Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 36 No. 1 › Management of Treatment...
GENERAL PSYCHOPHARMACOLOGY

Management of Treatment Refractory Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

Karen Dineen Wagner, MD, PhD
Psychopharmacology Bulletin 36(1) :130-142 , 2002/01/15

Abstract

Psychostimulants are the first-line treatment for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. A minimum of two psychostimulant trials should be instituted before a child’s symptoms of ADHD are considered treatment refractory. Clinical issues of diagnostic accuracy, comorbid disorders, psychosocial factors, medication compliance, symptoms across settings, and behavioral treatment should be addressed before initiating alternative medication trials. With the exception of tricyclic antidepressants, there is a paucity of controlled studies with adequate sample size to support the efficacy and safety of nonstimulant medications for the treatment of childhood ADHD. In this article, data on medications for treatment refractory ADHD in children and adolescents are presented and treatment strategies are discussed. Psychopharmacology Bulletin. 2002;36(1):130-142

Keywords

bupropion, clonidine, dextroamphetamine, guanfacine, methylphenidate, psychostimulant, tricyclic antidepressant

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In
Not yet subscribed? View subscription options

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Karen Dineen Wagner, MD, PhD. Management of Treatment Refractory Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Psychopharmacology Bulletin. 2002/01/15; 36(1):130-142.